Paul Gould
Family · Lakeville, MANPI 1801262316
Payments from drug & device makers
Across 644 payments — averaging $532.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$313K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$28K
- Alkermes, Inc.$335
- Axsome Therapeutics, Inc.$250
- Corium, LLC$219
- Johnson & Johnson$140
- plus $653 from 8 others
What the payments were for
- Consulting fees$3,7351%
- Speaking & faculty fees$262,61877%
- Travel & lodging$64,31519%
- Food & beverage$11,8943%
- Education$1470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 526 | $312,871 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 73 | $28,240 |
| Alkermes, Inc. | 11 | $335 |
| Axsome Therapeutics, Inc. | 2 | $250 |
| Corium, LLC | 5 | $219 |
| Johnson & Johnson | 4 | $140 |
| Sunovion Pharmaceuticals Inc. | 8 | $130 |
| Otsuka America Pharmaceutical, Inc. | 1 | $125 |
| Neurocrine Biosciences, Inc. | 1 | $114 |
| Lundbeck LLC | 5 | $88 |
| E.r. Squibb & Sons, L.L.C. | 1 | $83 |
| Eisai Inc. | 4 | $64 |
| Avanir Pharmaceuticals, Inc. | 2 | $36 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$342,708 in reported general payments places this provider in the 95th percentile of 2,320 family providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 265 | $432,753 |
| Invega TrinzaPaliperidone Palmitate | 17 | $136,022 |
| CaplytaLumateperone Tosylate | 36 | $67,070 |
| RexultiBrexpiprazole | 37 | $62,265 |
| Abilify MaintenaAripiprazole | 11 | $34,579 |
| Lurasidone Hcl | 70 | $23,097 |
| NuedextaDextromethorphan Hbr/Quinidine | 11 | $17,893 |
| Aripiprazole | 94 | $15,672 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 58 | $8,589 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 59 | $7,833 |
| DayvigoLemborexant | 33 | $7,453 |
| VyvanseLisdexamfetamine Dimesylate | 18 | $7,295 |
| TrintellixVortioxetine Hydrobromide | 14 | $6,821 |
| Quetiapine Fumarate | 333 | $5,522 |
| Clozapine | 38 | $4,275 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $312,871 | $432,753265 claims |
| Johnson & JohnsonInvega Trinza | $140 | $136,02217 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $125 | $96,84348 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $28,240 | $67,07036 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $36 | $17,89311 claims |
| Eisai Inc.Dayvigo | $64 | $7,45333 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,320 family providers in Massachusetts.
Other family in Lakeville
- Brittany MurrayBoston$141K
- Courtney NixonAmherst$81K
- Elizabeth WalshBrighton$80K
- Jennifer FlemingLawrence$80K
- Naomi AmudalaBoston$79K
- Geoffrey WhitleyCharlestown$66K
- Katherine O'BrienWinthrop$58K
- Kristy SmithActon$57K
- Leslie StefanowiczDartmouth$56K
- Marissa CasilloFoxborough$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.